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ABSTRACT

Depression is a significant problem for the managed care system. Antidepressant medication helps
ameliorate the symptoms of depression yet adherence to medication is known to be poor. The current
approach to adherence measurement (i.e HEDIS) is limited or lacking. Other methods are used (e.g
Proportion of Days Covered –PDC) in other chronic diseases to measure adherence. Medication adherence
is a growing concern for clinicians and other health care stakeholders (e.g. payer) because of the increasing
evidence that non-adherence is prevalent and places patients at an increased risk for adverse health
outcomes and higher cost of care.
We conducted a retrospective cohort study of patients enrolled in a Medicaid plan. For inclusion in
the study population patients had to meet HEDIS inclusion criteria and PDC criteria respectively. Patients
included in the HEDIS study’s cohort were adults at least 18 years of age with a new diagnosis of
depression confirmed by outpatient medication use and an ICD-9 diagnostic code. The upper limit age was
set at 75 years old in order to maintain the confidential information about the patients. Patients had to meet
certain enrollment eligibility criteria as well. For the PDC study population patients met the same age
requirement as for the HEDIS measurement inclusion criteria. Patients included in the study for the PDC
cohort were not required to have a new diagnosis of depression certified by a diagnostic code; they only
had to be antidepressant medication users during the study period. We evaluated antidepressant medication
adherence by applying the HEDIS measures and PDC measures. The measure of effect was the odds ratio
in separate models. We also applied HEDIS criteria to the PDS cohort to provide a head-to-head
comparison of the rates of adherence. Adherence was assessed with seven medication classes as
recommended by HEDIS: Miscellaneous Antidepressants. Monoamine Oxidase Inhibitors (MAOIs).
Phenylpiperazine

Antidepressants.

Selective

Serotonin-Norepinephrine

Reuptake

Inhibitors

Antidepressants (SSNRIs). Selective Serotonin Reuptake Inhibitors Antidepressants (SSRIs). Tetracyclic
Antidepressants (TeCAs). and Tricyclic Antidepressants (TCAs). Differences in baseline characteristics
and the odds of adherence were assessed between the groups for each methodology separately as well as
patient demographic and health related variables. We constructed multivariate logistic regression models to
measure the odds of adherence with antidepressant medication for each methodology while controlling for

potential confounders and assessing for interaction terms. The level of significance and the corresponding
95% confidence intervals of the odds ratios were presented as well.
A total of 626 eligible antidepressant users were identified according to the HEDIS criteria, and
22,351 eligible antidepressant users were identified according to PDC criteria and were evaluated for
adherence with antidepressant medication. In both study samples patients 50 years and older were
significantly more likely to be adherent with antidepressant medication than the younger group (<35 years )
patients. In both groups patients that had respiratory disease had an increased odds of adherence with
antidepressant medication relative to patients that were not classified having a respiratory disease. Patients
that had other mental health diagnoses in addition to depression had a statistically significant increased
odds of adherence with antidepressant medication relative to patients that did not have such diagnoses. The
beta coefficient representing the relationship between the antidepressant medication adherence and the
therapy regimen was positive and statistically significant for both samples. Patients that were using more
than one drug were significantly more likely to be adherent to antidepressant medication regimen than
patients that were using only one type of antidepressant drugs.
Our results implicate older age and comorbid diseases such as respiratory and other mental health
diseases and polymedication as risk factors associated with better adherence with antidepressant medication
therapy among Medicaid insured patients. Interventions that strive to improve adherence with
antidepressant medication therapy should continue to be implemented and evaluated.
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CHAPTER 1

INTRODUCTION

Medication adherence is a growing concern for clinicians, and other health system stakeholders
(e.g. payer) because of the increasing evidence that non-adherence is prevalent and associated with adverse
outcomes and higher cost of care.1 Adherence to a medication regimen is generally defined as the extent to
which patients take medication as prescribed by their health care providers.2 There are many different
methods for assessing adherence to medication. While there is no consensus about a golden standard for
measuring medication adherence, numerous subjective and objective medication adherence methods have
been developed. Oesterberg et al3 categorized these methods as either direct or indirect. Direct methods
include directly observed therapy, measurement of the level of the medicine or metabolite in the blood, and
measurement of the biological marker in the blood.3 Indirect methods of adherence assessment include
patient questionnaires, self reports, pill counts, rates of prescription refills, assessment of the patient’s
clinical response, electronic medication monitors, measurements of the psychological markers and patient
diaries.3
The American Psychiatric Association defines 2 phases of antidepressant treatment: acute phase
and continuation phase. The current Practice Guideline for the Treatment of Patients with Major
Depressive Disorder recommends pharmacological treatment for each phase to reduce the risk of relapse.
Patients having a successful acute phase treatment (adherence over 4-8 weeks) are encouraged to continue
treatment with antidepressant agents for at least 4 to 9 months. Moreover, for patients that had multiple
episodes of depression, further maintenance treatment is recommended for at least one year. 3
An ideal measure would evaluate adherence for all patients with depression. Unfortunately, unlike
other chronic diseases, no measures of medication adherence among chronic users of antidepressants have
been developed. The Pharmacy Quality Alliance (PQA) recommends using a proportion of days covered
(PDC) measure for calculating adherence for chronic users of medications for conditions such as diabetes
and dyslipidemia. Their measures are endorsed by the National Quality Forum (NQF). The PDC measure
calculates the percentage of patients that are taking the prescribed medications from a particular drug class
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that exceed an 80% adherence benchmark. The Medication Possession Ratio (MPR) is another metric that
measures medication adherence, yet this measure is considered inferior to the PDC because MPR is a mere
summation of the day supply, and does not consider multiple therapies. The PDC measure offers a more
conservative estimate of the medication adherence since it allows looking at each day in the designated
time period to determine whether an individual has one or more dispensed study drugs. As a proportion, the
PDC always ranges between 0 and 1. Typically, an 80% (0.8) threshold is applied to indicate good or poor
adherence, with higher thresholds set for some therapies (e.g. 90% for antiretrovirals).4
Depression is one of the most common disorders and a leading cause for disability worldwide.
Almost 50% of the U.S population has experienced at least one psychiatric disorder in their lifetime.5 The
lifetime prevalence of major depressive disorder is reported to be as high as 17% and the 12-month
prevalence is 5%-9%.6,7 The World Health Organization (WHO) considers major depressive disorder one
of the most debilitating diseases to society. Its negative outcomes include suicide, substantial impairment,
lower quality of life, increased health care utilization and cost, and adverse impact on employment
productivity.8 It is anticipated that major depressive disorder (MDD) will be the second leading cause of
disability worldwide by 20209 with a lifetime risk of 7% - 12% for men and 20%-25% for women.9
Depression is a serious public problem, particularly among people with low income. Low socioeconomic status is associated with a higher prevalence of depression. Moreover, the duration of new
episodes of depression are longer in people with a low socio-economic level.10 According to data from the
National Health and Nutrition Examination Survey (2009-2012) persons living below poverty level are
nearly 2½ times more likely to have depression than those at or below poverty level. 11
The incidence of depression is rising and the costs are escalating. People that have depression
cannot enjoy a fulfilled life because they experience sadness, a sense of isolation and feeling like they are a
burden. Depressed people are 30 times more likely to commit suicide and each year in U.S. approximately
41.000 individuals complete suicide.12
Depression impacts the academic development of a person, the marriage perspective and an
average loss of $10,400/year in income by the time the person reaches 50 years of age.13 Depressed people
are 7 times more likely to be unemployed.8 According to Smith JP et al (2010) a person that suffers from
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depression has a loss of 20% in potential income, and a lifetime loss for each family who has a depressed
family member of $300,000.14
From the employer point of view depression is a big concern also. The employer is affected by the
missed days of work (absenteeism) and the reduced productivity (presenteeism) of individuals with MDD.
According to data from the National Health and Nutrition Examination Survey (2009-2012) almost 43% of
individuals with severe depressive symptoms reported serious difficulties in work, home and social
activities. The rate of difficulty in work, home or social related activities, increased with the severity of
depression.11
The consequences of untreated depression or inadequately treated depression are significant,
therefore adherence to antidepressant medication is crucial. Response to drug therapy occurs predominantly
in patients who are strictly adherent to antidepressant medication regimens. Most patients experience good
outcomes with appropriate antidepressants taken for the appropriate period of time. Patients must be closely
monitored during the acute phase (first three months) and the initial continuation phase (the first six to nine
months) of treatment for necessary drug dosage adjustments. Measuring adherence is important to make
sure that patients comply with provider recommendations for a good outcome and a reduced economic
burden on health care system. The antidepressant therapy must be coupled with the appropriate form of
psychological therapy.
Antidepressant medications are the standard approach for treating depression. According to the
Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial, depressive disorder is
challenging to treat.14 STAR*D is the largest study of its kind. The results demonstrated that after exposure
to four different levels of medication intervention options, approximately one-third of the patients in this
study failed to achieve remission.14 Also, approximately 50% of the patients in this trial prematurely
discontinued antidepressant therapy for a number of different reasons, including patient-related (e.g. side
effects, misperception about medication), and clinician-related factors (e.g. poor instruction by the clinician
about the medication, lack of follow-up care). Depression itself is a condition that causes patients to have
difficulty following the medication regimen, yet they can have the greatest potential to benefit from
treatment adherence.15
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Currently, there are more than 20 antidepressant medications available worldwide, and they are
used singularly or in combination with other antidepressants to treat the disabling affects of depression for
many patients.
According to IMS Health National Prescription Audit PLUS, in 2010 antidepressants were the
second most commonly prescribed medication, second to drugs to lower cholesterol. Approximately 254
million antidepressant prescriptions were written in 2010, resulting in nearly $ 10 billion in costs. 16 Eleven
percent of Americans aged 12 years and over take antidepressant medication and more than 60% of patients
have taken therapy for 2 years or longer, with 14% having taken the medication for 10 years or more. 11 For
most patients, the course of major depressive disorder (MDD) is recurrent or chronic. The goal of
antidepressant treatment is the full remission of symptoms and prevention of relapse. Remission of
symptoms is related to improved functioning and prognosis. 17 Antidepressants are recommended to be
continued for at least 4 months beyond the initial symptom resolution. However, reported levels of nonadherence have been consistently high and this remains a serious concern. 18 Thus, a majority of
antidepressant users are chronic users of these medications, and as in other chronic diseases such as
diabetes and hypertension, the health system must direct resources towards promoting patient adherence
with prescribed chronic therapies.
The National Committee for Quality Assurance (NCQA) is a private standards-setting
organization which aims to improve the quality of health care and reduce the overall burden of illness. To
evaluate antidepressant adherence, NCQA uses the Antidepressant Medication Management (AMM)
measure from the Health Plan Employer Data and Information Set (HEDIS) standardized performance
measurement tool. HEDIS is a tool used by more than 90% of American health plans to measure
performance on important dimensions of care, including medication adherence. The HEDIS measure
focuses on newly diagnosed cases of depression, thus this measure is limited because it omits the majority
of the patients that are chronic users of antidepressants. The question that arises is how is adherence
measured for patients that use antidepressants chronically?
Another organization that has as a mission to improve quality of medication management is the
Pharmacy Quality Alliance (PQA). Among the quality measures developed by the Pharmacy Quality
Alliance (PQA), three quality measures are related to measuring medication adherence for chronic diseases
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such as diabetes, hypertension and cholesterol. The PQA adherence measures are endorsed by the National
Quality Forum (NQF) and are currently used by Centers for Medicare and Medicaid Services (CMS)
Medicare Part D plans.
The PQA identified medication adherence as an important component of medication-use quality
and endorsed the proportion of days covered (PDC) as standard method for calculating medication
adherence across prescription drug plans and pharmacies.4

Purpose and Hypothesis
The purpose of this study was to investigate the suitability of the PDC approach applied to
antidepressant adherence, in comparison with the HEDIS AMM measure. We sought to determine if the
percentage of patients identified as adherent with antidepressant medication according to the HEDIS
(AMM) specifications was similar to the percentage of patients identified as adherent with antidepressant
medication according to the PDC specifications during the chronic phase of treatment. In patients with a
confirmed diagnosis of depression (HEDIS) we calculated adherence with antidepressant treatment
according to the HEDIS specifications for chronic phase of adherence. Adherence was calculated for
patients that are users of antidepressant medication in the PDC group as well using 80% threshold standard
to the PDC methodology. Furthermore, we applied the HEDIS inclusion criteria to the PDC population to
determine the correlation between HEDIS and PDC adherence measurement methodologies in a unified
sample. Additionally, we evaluated several factors as predictors of adherence for both measures.
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CHAPTER 2

METHODOLOGY

The study was conducted as a retrospective cohort study using health care claims data describing
pharmacy utilization for a period spanning July 1, 2013-September 30, 2014. The data for this research
represent a sample of Medicaid recipients. These data contained information on enrollment and
demographics, as well as pharmacy and medical claims for approximately 40,000 enrollees utilizing
antidepressant medication.

HEDIS methodology inclusion and exclusion criteria.
Patients were at least 18 years of age as of July 1, 2013 and continuously enrolled for at least 180
days of a 231 day period between the period of July 1, 2013 to September 30, 2014. Patients older than 75
years of age were excluded from the study in order to maintain the confidentiality of subjects. All patients
were confirmed to have a diagnostic code for depression. International classification of disease ninth
edition (ICD-9) codes from the 2014 Healthcare Effectiveness Data and Information Set (HEDIS)19 were
used to identify the presence of any code indicative of depression or a depression related complication
(Appendix D). Also patients had to have a diagnosis of depression in an inpatient, outpatient, emergency
department, intensive outpatient or partial hospitalization setting during the 60 days prior of the starting of
medication through 60 days after the Index Prescription Start Date (IPSD). All patients were confirmed to
have used a medication for treatment of depression or a depression related disease, defined as the presence
of a claim for any oral or injectable antidepressant agent during each patient’s continuous enrollment
period. Medication use was evaluated 105 days prior to the IPSD with seven medication classes (Appendix
E) in order to test the negative medication history (NMH). Patients that had a prescription during the NMH
period were excluded from the study, thus providing a sample of newly treated patients.
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PDC methodology inclusion and exclusion criteria.
Patients were at least 18 years of age as of July 1, 2013 and continuously enrolled for 365 days
during the study period. Patients older than 75 years of age were excluded from the study in order to
maintain the confidentiality of subjects. No ICD-9 codes for a diagnostic of depression were required for
the PDC methodology inclusion criteria. Patients that used any of the antidepressant medications from the
seven classes (Appendix E) were included in the study. Patients were also required to have at least 91 days
between the index medication and the end of the study period.

Defining Adherence
Eligibility for the HEDIS methodology required that all patients have at least one antidepressant
claim during the index period associated with an ICD-9 diagnostic of depression 60 days prior or after the
first prescription. This will ensure that the patients has a new diagnosis of depression according to HEDIS
requirements. Patient must not have an antidepressant claim during a 105 days period prior to the index
date. Patient with a claim during the negative medication history were excluded from the study population.
The continuation phase of the treatment lasts 231 days, during which a patient needs to fill a sufficient
number of antidepressant prescriptions to provide medication for at least 180 days. Medication gap due to
washout or refill can total a maximum of 51 days during the 231-day period. Adherence was determined as
the proportion between the days supply of dispensing divided by the days of follow up during the chronic
phase (231 days) . Patients were classified as adherent if they remained on antidepressant medication for at
least 180 days (6 months) of the 231 days in the period.
For the PDC methodology, all patients were required to have at least one antidepressant claim
during the index period. The index date should occur at least 91 days prior to the end of the study period.
Adherence was also evaluated as a dichotomous variable and calculated as the proportion between the days
supply of dispensing during the study period divided by the number of days between the fill days and the
end of the study period. According to the Pharmacy Quality Alliance (PQA) patients will be considered
adherent to their medication if the PDC is equal to or exceeds 80% and non-adherent if the PDC is less than
80%. Adherence with antidepressant medication was evaluated separately for the two methodologies as the
inclusion criteria for the measures were different, yielding different samples.

7

Independent Variables
Age: We created three age groups, approximately the youngest, middle aged, and older patients in the
population. Most older adults 65 years old or older receive their prescription drugs benefit through
Medicare Part D plans, and were not included in this study.
Gender: Analyzed as a dichotomous variable.
Individual Comorbid Diseases: The presence of diabetes, cardiovascular, respiratory and mental health
diseases (other than depression) was identified during the entire study period using the ICD-9 codes from
the HEDIS 2015 (Appendix A, B, C, D). The diabetes disease variable comprised codes for diabetes with
and without complications and also codes for the drug therapeutic class.(Appendix A). The cardiovascular
disease variable comprised codes for congestive heart failure, coronary artery disease, myocardial
infarction, and other forms of ischemic and non-ischemic cardiovascular disease (Appendix B). Respiratory
disease comprised codes for bronchitis, emphysema and asthma. Mental health disorders comprised codes
for schizophrenia, bipolar disorder, paranoia, psychosis, anxiety, autism, panic disorder, personality
disorders, acute stress disorders, impulse control disorders, anger/ aggression disorders, attention deficit
disorder, and attention hyperactivity deficit disorder. These four conditions were selected based on high
prevalence and high health expenditure.
Physician care visits: We analyzed if patients visited a physician providing a basis for qualifying patients
as seeing a medical doctor or not visiting a physician during the follow-up period.
Medication regimen: The antidepressant medication regimen was calculated as the number of unique
antidepressant types dispensed during the study period providing a basis to classify patients as users of
antidepressant monotherapy or polytherapy.

Statistical Analysis
The analysis of the data was performed using Statistical Analysis Software Version 9.4 (SAS®
Version 9.4). The Pearson Chi-Square test was used to assess differences between groups (within each
measure separately). Continuous variables were compared using t-tests for independent samples. The

8

relationship between HEDIS/PDC and adherence, are presented as frequencies and percentages of patients
that were adherent to antidepressant medication according to each characteristic. Results with a P-value
<=0.05 were considered statistically significant while p-values <0.2 were used in selecting variables for
inclusion in the multivariate model. Univariate logistic regression was used to assess each individual
variable and the results with the P-values are

presented with odds ratios and corresponding 95%

confidence intervals. Multivariate logistic regression was used to assess the relationship between the
independent variables describing patient and provider characteristics, and the dependent variable of
medication adherence, measured by the AMM and PDC methods. Antidepressant medication adherence
was the risk factor of interest, with all other independent variables considered potential confounders of the
relationship with the dependable variable of adherence. These models were created using a stepwise
approach removing the least statistically significant interaction terms at each step. Two-way interactions
were assessed using a hierarchical approach. The likelihood ratio test was used to compare models in order
to evaluate if the inclusion of interaction terms improved the model fit. The difference in the -2 log statistic
between the full model and the reduced model was compared to the corresponding Chi-square statistic with
the degrees of freedom equal to the difference in the number of terms in the models. Multivariable
colinearity was assessed for all the possible confounders for each model (both for HEDIS and PDC
measures). The adherence beta estimate for the full model with all variables was used as the standard for
comparison. The final multivariate model for both HEDIS and PDC measures contained all important
variables for model inclusion. The Akanke Information Criterion statistic and the Hosmer-Lemeshow
goodness of fit test were used to assess the fit of the final models.
A third sample was created by applying the inclusion and exclusion criteria for PDC methodology
to patients that met the HEDIS inclusion and exclusion criteria. The sample was analyzed to determine if
there is a correlation between measuring adherence with antidepressant medication using HEDIS and PDC
methodology using a continuous measure of adherence.
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Resources required
The journal articles, clinical guidelines and other important information necessary for the
successful completion of this research were obtained using the University library or interlibrary exchange
services, PubMed through the College of Pharmacy, or other professional services available on World
Wide Web such as government information policy on HEDIS and PDC measures. Data used in this study
were provided by Major Professor Stephen Kogut. This study was approved by URI Institutional Review
Board. Analyses of the data were conducted using SAS® Version 9.4 -University of Rhode Island.
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CHAPTER 3

RESULTS

The two separate samples were created after applying the inclusion/exclusion criteria for both
HEDIS and PDC methods that were subsequently statistically analyzed. The main difference between the
samples created is that patients included in the HEDIS sample have a new diagnosis of depression
documented by an ICD-9 code, whereas the patients in the PDC sample are simply antidepressant users
irrespective of diagnosis.

Application of inclusion and exclusion criteria for HEDIS methodology
The final cohort comprised a total of 626 Medicaid patients that met all the inclusion and
exclusion criteria for HEDIS methodology (Figure 1). The initial cohort was comprised of 32,052 patients
initially from which a number of 15,056 patients were excluded because they did not met the enrollment
criteria and had no prescription for an antidepressant drug during the study period. Further 22,370 patients
were excluded from the cohort for (1) not having a diagnosis of depression according to a ICD-9 code, (2)
not being prescribed an antidepressant agent during the intake period and (3) not meeting the eligibility
criteria according to HEDIS requirements.

Application of inclusion and exclusion criteria for PDC methodology
The final cohort was comprised of 22,351 patients (Figure 2). Initially a total number of 34,481
patients were identified as using an antidepressant medication agent. After selecting only the patients that
had an antidepressant prescription during the study period, 1,352 patients were excluded. After applying
the continuous enrollment criteria another 1,591 patients were excluded from the sample. Further, 5,190
patients were excluded from the sample because they (1) did not use an antidepressant agent included in the
study criteria and (2) their index medication was not greater than 91 days prior to the end of the study
period.

11

HEDIS Baseline Characteristics
The analytic cohort for the HEDIS measure was comprised of 626 patients (Table 1). Patients in
this cohort had a new diagnosis of depression documented by o a ICD-9 code. The mean (standard
deviation [SD]) age of enrolled patients was 37.59 [12.16]. The majority of the cohort was female
representing 79.52% of the cohort sample and only 20.48% were male . The prevalence of diabetes,
cardiovascular, respiratory and mental health disease was different between groups. Patient with diabetes
comprised 7.35% of the HEDIS group. Patients with cardiovascular disease made up 13.42% of the HEDIS
group, patients with respiratory disease made up 6.55%, whereas patients with mental health disorders
made up 33.07% of this sample. In terms of the health care utilization, 27.48% of HEDIS patients were
hospitalized during the study period and 74.60% visited a psychiatrist. Variability existed with regard to the
therapeutic regimen, with 57.99% of patients taking a single antidepressant drug during the study period.
Approximately sixty-six percent of the patients were prescribed a selective serotonin reuptake inhibitor
(SSRI) medication, 12.62% of the patients were prescribed trazodone, while 8.31% of the patients were
prescribed bupropion. Selective norepinephrine reuptake inhibitors (SNRIs) agents and tricyclic (TCAs)
antidepressants were prescribed to 4.95% of the patients and 4.63%, respectively. Patients that were
prescribed mirtazapine accounted for 3.35% of the sample.

PDC Baseline Characteristics
The analytic cohort for PDC measure was comprised of 22,351 patients (Table 1). Patients in this
cohort are users of antidepressant drugs and did not have a diagnostic of depression according to an ICD-9
code. The mean (standard deviation [SD]) age of enrolled patients was 42.76 [12.42]. The majority of the
cohort was female representing 72.14%% of the cohort sample, and only 27.86% were males. The
prevalence of diabetes, cardiovascular, respiratory and mental health disease was different between groups.
Patient with diabetes made up 11.69% of the group. Patients with cardiovascular disease made up 14.45%
while patients with respiratory disease made up 6.17% of the group. Other mental health disease was
present in 21.28% of the PDC group. In terms of the health care utilization, 16.71% of patients were
hospitalized during the study period and 36.54% had a physician visit. Therapeutic regimens varied and
69.50% of patients took a single antidepressant drug during the study period. Approximately 66% percent
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of the patients were prescribed a serotonin reuptake inhibitor (SSRI) medication, while 11.91% of the
patients were prescribed trazodone, and 10.04% of the patients were prescribed bupropion. Selective
norepinephrine reuptake inhibitors (SNRIs) agents and tricyclic (TCAs) antidepressants were prescribed to
patients in 7.49% and 9.98% of the cases, respectively . Patients that were using mirtazapine accounted
for 3.62% of the PDC sample.

Adherence with antidepressant medication according to HEDIS methodology
The bivariate relationships between the dependent variable, adherence with antidepressant
medication according to HEDIS methodology, and all other variables are presented as frequencies and
percentages in Table 2. Patients were considered adherent if they met or exceeded the HEDIS adherence
threshold of 180 of 231 days else they were considered non-adherent. The overall adherence for the HEDIS
measure was 37.38% with 234 of the 626 patients taking their medication as prescribed by their provider.
Significant differences between adherent and non-adherent patients existed across all three age stratum (Pvalue <0.001). The highest level of adherence was registered among older patients in the over 50 age
group, and the lowest level of non-adherence (28.67%) was among the younger group of individuals (less
than 35 years of age). Approximately thirty-eight percent of females were adherent to the antidepressant
medication regimen compared with 35.16% of males, without a statistical significant difference (P-value=
0.6091). Among patients that had a diagnosis of diabetes, 45.65% were adherent to the antidepressant
medication therapy, but without significant difference from patients without diabetes (P-value=0.2678).
Patients with cardiovascular disease were adherent to antidepressant medication therapy at 44.05%, which
did not differ from the rate among patients without cardiovascular disease (P-value=0.1838). Patients with
respiratory disease were more frequently adherent (56.10%) than patients without this condition (P-value=
0.0123). Adherence among patients with other mental health disease (42.03%) did not differ statistically in
terms of adherence with antidepressant medication compared with the patients that did not have diagnoses
for other mental health conditions (P-value= 0.0958). Related to health care utilization, 39.40% of patients
that visited a psychiatric practitioner and 39.79% of hospitalized patients, were adherent to the medication
regimen; however, neither of these comparisons yielded statistically significant differences (P-value=
0.0874 and P-value=0.9264, respectively). Adherence rates varied among the antidepressant medication
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drug classes with no statistical difference between the adherent and non-adherent groups. Adherence
among patients utilizing antidepressant polytherapy was 49.43%, which was statistically significantly
greater than adherence among users of monotherapy (P-value<0.001).

Adherence with antidepressant medication according to PDC methodology.
The bivariate relationship between the dependent variable, adherence with antidepressant
medication according to the PDC methodology, and all other variables are presented as frequencies and
percentages in Table 2. Patients were considered adherent if they met or exceeded the adherence threshold
of 80%, else they were considered non-adherent. The overall adherence rate according to the PDC measure
was 50.37% with 11,259 of 22,351 patients taking their medication as prescribed by their provider.
Significant differences between adherent and non-adherent patients existed across all three age stratum (Pvalue<0.001). The highest level of adherence was registered among older patients in the >50 years of age
group, 61.85% compared with 37.12% in the youngest age group (P-value<0.001). The proportion of
female patients that were adherent to the antidepressant medication regimen compared to the proportion of
males that adherent was 50.00% to 51.33% , without a statistically significant difference (P-value=
0.0758). In terms of the comorbid conditions, all the differences between the presence/absence of the
condition with adherence rates were statistically significant with a P-value<0.001. Among patients that had
a diagnosis of diabetes, 61.35% were adherent to the antidepressant medication therapy, which exceeded
adherence rates for patients without diabetes (P-value <0.001). Patients with cardiovascular disease were
adherent to antidepressant medication therapy at 58.85%, which exceeded adherence among patients
without cardiovascular disease (P-value <0.001). Patients with respiratory disease (62.19%) and other
mental health diseases (54.38%) that were adherent to the antidepressant medication therapy differed
statistically significant from those without these conditions (37.81% and 45.62%, respectively) with Pvalues<0.001. Related to health care utilization, the group of patients that visited a psychiatric practitioner
during the follow up period were adherent in a proportion 56.01%, which exceeded the rate among patients
lacking such visits (P-value <0.001). Among patients with at least 1 hospitalization during the period,
51.75% were adherent to the medication regimen; the adherence rate among patients that were not

14

hospitalized was not statistically significantly different (P-value=0.0645). Users of SNRIs and trazodone
were more frequently adherent than users of SSRIs. TCAs, and mirtazapine (P-value<0.001).

Univariate Logistic Regression Analyses for HEDIS and PDC methodologies
Univariate logistic regression analyses were performed for both methodologies in order to test the
association of each explanatory variable separately with the outcome (adherence with antidepressant
medication) in order to identify variables for inclusion in the multivariate analyses. We also excluded the
variables from the further analysis that did not show significant association with the outcome (adherence
with antidepressant medication) on their own as they are not likely to be associated with the outcome after
adjusting for other variables. The results of the univariate logistic regression for all the variables considered
in the analysis are presented in Table 3. For both methodologies, the middle and older age groups had
statistically significant positive beta coefficients that showed the association of age with the outcome
(adherence with antidepressant medication). The Odds Ratios were >1 for both age groups for both
methodologies, having 95% confidence intervals that did not overlap unity. A statistically significant
positive association [Odds (95% CI)] between the respiratory disease and the outcome was found for both
methodologies with [OR 2.265 (1.159 - 4.293)] for HEDIS cohort and [1.672 (1.494 - 1.870)] for PDC
cohort, with P-values<0.001.

Likelihood of antidepressant medication adherence according to HEDIS selected characteristics
The results of the multivariate logistic regression analysis of the effect of antidepressant therapy
on medication adherence according to HEDIS methodology are presented in Table 5. Collinearity was not
found between any of the independent variables assessed for the inclusion into the model. Interaction
between variables was assessed as well to decide whether any interaction terms should be included into the
final model. No significant interactions were found. The likelihood ratio chi-square was used to decide on
the best model and was calculated by subtracting the -2log likelihood of the model with the variable from
the nested model (Nested model= the model without the variable). The Hosmer-Lemeshow goodness of fit
test showed that that the model was an appropriate one (p > 0.05) The beta coefficients representing the
relationship between antidepressant medication adherence and age group 35-49, and group age older than
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50 years, were statistically significant (0.3190 and 0.9463 respectively [P-value<0.001]). Patients 50 years
and older were significantly more likely to be adherent with antidepressant medication than those less than
35 years old (OR 2.576 [95% CI 1.626 – 4.083]). Patients that had respiratory disease had an increased
odds of adherence with antidepressant medication relative to patients that were not-adherent and suffered
from a respiratory disease (OR 1.745 [95% CI 0.894 – 3.406]). Patients that had a mental health disease
had increased odds of adherence with antidepressant medication relative to patients that were not-adherent
and had the same comorbid condition (OR 1.379 [95% CI 0.964 – 1.973]). The beta coefficient
representing the relationship between the antidepressant medication adherence and the therapy regimen was
positive and statistically significant (0.3213 [P-value<0.001]. Patients that were using more than one
antidepressant were significantly more likely to be adherent to antidepressant medication regimen than
patients that were using only one type of antidepressant drugs (OR 2.214 [95% CI 1.570 – 3.121]).

Likelihood of antidepressant medication adherence according to PDC selected characteristics
The results of the multivariate logistic regression analysis of the effect of antidepressant therapy
on medication adherence according to PDC methodology are presented in Table 6. Collinearity was not
found between any of the independent variables assessed for the inclusion into the model. Interaction
between variables was assessed as well to decide whether any interaction terms should be included into
the final model. The interactions found between the independent variables are discussed in the limitations
section of the paper, as the interactions terms were not suited to be included in the final model. The
likelihood ratio chi-square was used to decide on the best model and was calculated by subtracting the 2log likelihood of the model with the variable from the nested model. The goodness of fit test showed that
that the model was an appropriate one. The beta coefficients representing the relationship between
antidepressant medication adherence and age group 35-49, and group age older than 50 years, were
statistically significant (0.5484 and 1.0101 respectively [P-value<0.001]). Patients 50 years and older
were significantly more likely to be adherent with antidepressant medication than the less than 35 years old
patients (OR 2.746 [95% CI 2.564 – 2.940]).
The beta coefficient representing the relationship between adherence with antidepressant
medication and diabetes was statistically significant (0.5051 [P-value<0.001]). Patients that had diabetes
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were significantly more likely to be adherent with antidepressant medication than patients that did not
have diabetes (OR 1.657 [95% CI 1.524 – 1.802]). The beta coefficient representing the relationship
between adherence with antidepressant medication and cardiovascular disease was statistically significant
(0.4003 [P-value<0.001]). Patients that had cardiovascular disease were significantly more likely to be
adherent with antidepressant medication than patients that did not have cardiovascular disease (OR 1.492
[95% CI 1.384 - 1.609]). Patients that had respiratory disease had a statistically increased odds of
adherence with antidepressant medication relative to patients that were not-adherent and suffered from a
respiratory disease (OR 1.672 [95% CI 1.594 – 1.870]). The beta coefficient representing the relationship
between the adherence with antidepressant medication and other mental health disease was statistically
significant (0.2042 [P-value<0.001]. Patients that had a mental health disease had a statistically increased
odds of adherence with antidepressant medication relative to patients that were not-adherent and had the
same comorbid condition (OR 1.227 [95% CI 1.150 - 1.308]). Patients that were using more than one
antidepressant were significantly more likely to be adherent to antidepressant medication regimen than
patients that were using only one type of antidepressant drugs (OR 4.807 [95% CI 4.509 - 5.125]). Patients
that used SNRIs were statistically more likely to be adherent to antidepressant regimen compared with
those that were not taking an SNRI drug (OR 1.740 [95% CI 0.789 - 0.878]).

Correlation between adherence with antidepressant medication using HEDIS and adherence with
antidepressant medication using PDC methodology
The final cohort comprised a total of 626 Medicaid patients that met all the inclusion and
exclusion criteria for HEDIS methodology applied to the PDC sample. The sample was analyzed to
determine if there is a correlation between measuring adherence with antidepressant medication using
HEDIS and PDC methodology. We calculated the correlation coefficient of the two variables and we found
that the two methodologies are highly positively correlated with a correlation coefficient of 0.95. This
means that the two variables are closely correlated and that if we measure adherence with antidepressant
medication according to HEDIS methodology for patients that meet the PDC criteria, in 95% of the cases
they will be found adherent. A correlation matrix plot is presented in Figure 3.
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CHAPTER 4

DISCUSSION

Major depressive disorder is a prevalent and debilitating disease among the U.S adult population.
Effective treatment and adherence with antidepressant medication regimen is essential for optimal
therapeutic outcome and for lower economic implications. Depression is a chronic disease, and many
patients will be taking medication for long periods of time, maybe lifelong. According to the World Health
Organization (2003) “adherence is the extent to which a person’s behavior in taking medication
corresponds with agreed recommendations from the health care provider” 2 and that adherence is a
multidimensional phenomenon determined by the interplay of five sets of factors: socio economic, health
care system, condition related, therapy related and patient related. Moreover, WHO stresses the fact that
the consequences of non-adherence are may be very serious, and if non-adherence were a disease, it could
be termed an “epidemic”.2
Efforts are being made by institutions, clinicians and professional organizations to determine the
most effective interventions to improve patient’s adherence. While medication adherence for chronic
diseases such as diabetes and hypertension have well established measures, adherence with antidepressant
medication is only measured for new diagnosed patients, leaving aside the chronic users of antidepressants.
Further research is needed to better address how medication adherence is measured among patients with
chronic depression.
The present study investigated if there is a difference between the percentage of patients identified
as adherent with antidepressant medication according to AMM specifications and the percentage of patients
identified as adherent with antidepressant medication according to the PDC specifications during the
chronic phases of treatment. It was hypothesized that the predictors of non-adherence will be similar for the
HEDIS and PDC methodologies. The effect of older age on adherence with antidepressant medication
[Odds ratio (95% CI)] was consistent between the two groups, as age was a significant risk factor for nonadherence with antidepressant medication for both HEDIS [OR 2.576 [95% CI 1.626 – 4.083])] and PDC
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patients (OR 2.746 [95% CI 2.564 – 2.940]). This is possibly explained by the fact that older people take
more medication as compared to the younger patients, hence more prone to be considered adherent.

As expected, the effect of polymedication on adherence [Beta estimate (P-value)] was consistent
between the two analyzed groups [0.3213 (P-value<0.001)] for HEDIS and [1.5701(P-value<0.001)] for
PDC we considered in our analysis that no more than two drugs were prescribed for same medical
condition and coded polytherapy by looking at the drugs filled in the same day. We excluded from our
analysis one of the drugs refilled in the same day during our study period. A limitation of the HEDIS
method is that it does not adequately discern between combination therapy and medication switch. Thus,
patients using more than more type of antidepressant are more likely to be classified as adherent. The
univariate models for HEDIS methodology [Odds ratios (95% CI)] supported to lack of direct association
between diabetes and cardiovascular diseases and adherence with antidepressant medication [OR 1.447
(95% CI 0.971 - 2.648)] and [OR 1.379 (95% CI 0.866 – 2.195)] respectively. The multivariate model for
PDC methodology [Odds ratios (95% CI)]

supported the association between adherence with

antidepressant medication and chronic comorbid conditions such as diabetes and cardiovascular diseases
[OR 1.675 (95% CI 1.524 – 1.802)] and [OR 1.492 (95% CI 1.384 – 1.609)] respectively. The latter finding
aligns with the findings of a study by Katon et al20 concerning adherence with antidepressant drug therapy
in patients with evidence of diabetes or cardiovascular disease, or both. Patients adherent with
antidepressant medication were more likely to be adherent to comorbid therapy versus those non-adherent
to antidepressant drug therapy (Odds ratio [OR], 2.13 for cardiovascular, [OR] 1.85 for diabetes, [OR]
1.45, P-values<0.001 for both).20
Factors associated with medication adherence are dependent upon the characteristics of the patient
population, the medication class and data source evaluated. According to the World Health Organization
(2003) “adherence is the extent to which a person’s behavior in taking medication corresponds with agreed
recommendations from the health care provider”2 and that adherence is a multidimensional phenomenon
determined by the interplay of five sets of factors: socio economic, health care system, condition related,
therapy related and patient related. A study by Akincgil el al21 looked at adherence with antidepressant
medication among privately insured patients diagnosed with depression. The study used medical and
pharmacy claims data for 4312 subjects that were continuously enrolled in the health plan with a new
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diagnostic of depression and who initiated antidepressant treatment. Treatment adherence was assessed for
acute phase and continuation phase using the Health Plan Employer Data and Information Set (HEDIS)
quality measures for outpatient depression care. The results showed that 51% of patients were adherent
through acute phase.

Older age and higher economic status were associated with better adherence.

Alcohol and other substance abuse predicted lower acute-phase adherence (OR=0.49 and OR=0.72
respectively) for patients having two or more cardiovascular/metabolic conditions (OR=0.65), and for those
who started treatment with an older generation antidepressant (OR=0.69). The presence of follow up visits
from a psychiatrist positively influenced adherence. (OR=1.19). Among patient adherent during the acute
phase, 41.5% remained adherent during the continuation phase. Adherence was significantly lower for
Health Maintenance Organizations (HMO) enrollees compared with indemnity enrollees (OR=0.62). 22
According to Jeon-Slaughter22 low level income combined with health insurance status and race/ethnicity,
predict non-adherence to antidepressant treatment. The study extracted data from the National Comorbidity
Survey-Replication (NCR-R) and the sample study comprised 280 adults between age 18 and 64 who were
diagnosed with major depressive episode according to DSM-IV at some point during their lifetime and
medicated with SSRIs in the past 12 months. The study results stated that African Americans were at
higher risk of medication noncompliance that whites (Odds ratio, 4.53) and major depressive episode
comorbidity was positively associated with medication noncompliance (Odds ratio, 4.52).23
Strategies to improve adherence with antidepressant medication therapy involve pharmacists,
educational interventions involving physicians, nurses, different tools and structures that health plans may
use to improve depression care. Finley et al23 assessed the effect of collaborative care model with emphasis
on the clinical pharmacist in providing drug management and treatment follow up to patients with
depression. They compared the outcomes of subjects treated in the collaborative model (75 patients) with
subjects receiving usual care (50 patients). After 6 months, the intervention group demonstrated a
significantly higher drug adherence rate than the control group (67% vs 48%, odds ratio 2.17, 95%
confidence interval 1.04 -4.51, p=0.038).23 Another study by Hoffman et al24 evaluated the impact of mailbased physician and member educational interventions on patients adherence with antidepressant
medication. The study was a prospective randomized controlled one that followed 9564 patients over 6
months after filling a new prescription of antidepressant medication. A pharmacy claim claims database
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was used to identify patients and track medication adherence. Practitioners were randomly assigned to
intervention and control group. Patient assignment was linked to their physician’s assignment. After
adjusting the variables, the intervention statistically significant impacted the adherence [95% CI (1.003 –
1.197) p<0.01] proving that a monthly mail-based educational intervention program can positively
influence patient adherence to therapy.24
Correlation between the two methodologies proved that adherence with antidepressant medication
can be measured using the PDC method used for measuring adherence with medication for chronic
diseases.
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CHAPTER 5

LIMITATIONS AND CONCLUSIONS

The present study utilized a retrospective cohort design with variables derived from data based
claims of insured patients in a Medicaid state program. Because of the nature of the data we lack
information on race/ethnicity, disease severity, social support of perceived stigma of patients with
depression. Adherence is a problem that touches more than one level and poor adherence can be influenced
by factors such as knowledge, attitudes, skills, environment of the patient and providers’ practices. Due to
the retrospective, not-randomized study design and the use of claims data we couldn’t analyze all the
variables that might have influenced adherence with antidepressant medication regimen. Because we
captured only comorbid disease states through ICD-9 coding only during the study period, we might have
underestimated the comorbid disease prevalence. There is a potential for misclassification surrounding the
outcome (adherence) considering that patients that were prescribed two drugs on the same day were
classified as using polytherapy. Some interactions were found between age and therapeutic regimen.
Adults over 35 years old were more likely [OR (95% CI)] to use more than one drug and be adherent more
often compared with the younger patients; the age group 35-49 years [1.415 (1.205 – 1.661), the age
group older than 50 years [1.642 (1369 – 1.970)] with statistical P-value<0.001. Also, when more drugs
were dispensed, the SSRIs were more likely to be prescribed [0.402 (0.318 – 0.509)] with a P-value<0.001.
We derived measures of adherence from claims data rather than observing actual medication use. It is
possible that patients picked up medication but then did not proceed to take it, resulting in a
misclassification of baseline adherence.
Our study is believed to be the first evaluating the correlation between the measuring adherence
with antidepressant medication according to HEDIS methodology and PDC methodology, so there was no
evidence in the literature to support our findings. The generalization of our results is limited and
confirmation of our results is to be warranted.
In conclusion, in both cohorts age (over 35 years) was found to be a risk factor for adherence with
antidepressant medication for both groups. Patients that had respiratory disease had an increased odds of
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adherence with antidepressant medication relative to patients that did not have a respiratory disease.
Patients that had a mental health disease had increased odds of adherence with antidepressant medication
relative to patients that did not have these comorbid conditions. Patients that were using more than one
drug were significantly more likely to be adherent to antidepressant medication regimen than patients that
were using only one type of antidepressant drugs.
The methodologies of measuring adherence are closely correlated and that

if we measure

adherence with antidepressant medication according to HEDIS methodology for patients that meet the
PDC criteria, in 95% of the cases they will be found adherent. The findings of this study suggest that PDC
methodology may be a suitable method of measuring adherence with antidepressant medication. The larger
sample size for PDC methodology gives it some advantages over the HEDIS methodology sample: (1) is
more representative of the population being analyzed and the results can be generalized to larger population
with confidence, (2) greater accuracy of the results, (3) diversity and outliers are captured and observing
them would give a more accurate picture of the characteristics of the population, dividing the sample into
smaller sample groups can give deeper and valuable information about the population.
Patients using antidepressants should be adherent regardless of indication for use. Because HEDIS
methodology limits the measuring of adherence only to new patients with and ICD-9 diagnosis of
depression, a large percent of patients that might have another diagnosis/ or no diagnosis at all, are not
considered for adherence measurement. Another aspect is represented by the fact that there is currently no
measure in place to quantify adherence with antidepressant medication for chronic depression.
HEDIS methodology of measuring adherence with antidepressant medication has some
limitations. Antidepressants may be prescribed by non-psychiatrists to treat medical disorders in the
absence of a psychiatric diagnosis According to US Department of Health and Human Services 200825, 23
% of U.S. adults had a mental health problem treated in the past year by a general medical provider
(physician, nurse, or other health professional), 16 % by a non-psychiatrist mental health specialist, 12 %
by a psychiatrist, 8 % by a human services provider, and 7 % by a complementary and alternative medical
provider. Not all of these professions might be a as expert in diagnosis and treating depression. 25
Other limitation of HEDIS is that looking back 105 days might not be long enough and thus some
cases are not new users; it does not exclude patients that were misdiagnosed with depression; it relies on
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pharmacy dispensing records which may not represent medication actually taken by the patient. People
might be dually enrolled during the study period they might be eligible for Medicare, but not have the
Medicaid part. Another limitation of the approach is the duration of therapy. Not all patients need to use
antidepressant medication indefinitely, regardless of diagnosis. This means that some patients may be
considered non-adherent with antidepressant medication when applying the method, although the patient
may have legitimately ended the treatment at the provider’s recommendation.
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Figure 1. Eligibility Flowchart: Application of Inclusion and Exclusion Criteria for HEDIS
methodology

38,052 unique patient IDs

No prescription claim for an
antidepressant
(exclude 4,659 )

N = 33,393

No continuous enrollment
(exclude 10,397)

N = 22,996

Not using antidepressant medication
during the intake period
(exclude 18,160)
(exclude xxx)
N = 4,836

Absence of ICD-9 code for depression
(exclude 3,917)

N = 919

Do not have the eligibility criteria
(exclude 293)

N = 626
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Figure 2. Eligibility criteria for Inclusion and Exclusion Criteria for PDC methodology

34,481 Patients using antidepressant
medication

No prescription during the study period
(exclude 1,352)
(exclude xxx)
N=33,129

No continuous enrollment
(exclude 1,591)
(exclude xxx)
N=31,538

Not using the antidepressant included
in the study design
(exclude 2,871 )
(exclude xxx)
N=28,667

Not being enrolled at least 91 days
prior to end of the study period
(exclude 6,316)
(exclude xxx)
N=22,351
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Table 1. Baseline Characteristics of Patients Identified for Antidepressant Adherence Measurement
Using HEDIS1 and PDC2 methodology
Characteristic

HEDIS1
N = 626
% (n)

PDC2
N = 22,351
% (n)

Age, years
Mean Age [SD]

37.59 [12.16]

42.76 [12.42]

% (n)
44.73 (280)
35.30 (221)
19.97 (125)
% (n)
% (n)
20.48 (128)
79.52 (497)

% (n)
29.43 (6579)
37.06 (8242)
33.50 (7488)

Age < 35
35 < Age <49
50 ≤ Age
Gender
Male
Female
Comorbid Disease

P value

92.65 (580)
85.58 (542)
93.45 (585)
66.93 (419)

6.17 (1178)
21.28 (4757)

20973 (93.83)
78.92 (17594)

0.694
<0.001

Absent
(n)
25.40 (159)
72.52 (454)

Present
%
36.54 (8168)
16.71 (3735)

Absent
(n)
63.46 (14183)
83.29 (18616)

P value

Absent
Present
Absent
% (n)
% (n)
Monotherapy
57.99 (363)
42.01 (263) 69.50 (15534)
30.50 (6817)
SSRI3
65.81 (412)
34.19 (214) 56.81 (12643)
43.19 (9611)
SNRI4
4.95 (31)
95.05 (595)
7.49 (1667)
92.51 (28587)
Trazodone
12.62 (79)
87.38 (547)
11.91 (2651)
88.09 (19603)
TCA5
4.63 (29)
95.37 (597)
9.98 (2221)
90.02 (20033)
Bupropion
8.31 (52)
91.69 (574)
10.04 (2235)
20019 (89.96)
Mirtazapine
3.35 (21)
96.65 (605)
3.62 (805)
96.38 (21449)
1
HEDIS - patients have a diagnosis of depression
2
PDC- includes all users of antidepressants irrespective of diagnosis
3
SSRI-Selective Serotonin Reuptake Inhibitors Antidepressants,
4
SNRI-Selective Serotonin-Norepinephrine Reuptake Inhibitors Antidepressants,
5
TCA-Tricyclic antidepressants

P value

Cardiovascular
Respiratory
Mental Health
Health Care
Utilization
Psychiatric visits
Hospitalization
Therapy Regimen

6.55 (41)
33.07 (207)
Present
%
74.60 (467)
27.48 (172)

(n)

Present

*

Present

< 0.001

Absent
(n)
88.31 (19738)
85.55 (19121)

%
7.35 (46)
13.42 (84)

Absent

< 0.001

%
11.69 (2613)
14.45 (3230)

Diabetes

Present

% (n)
27.86 (6228)
72.14 (16123)

P value

0.008
0.468

< 0.001
<0.001

<0.001
<0.001
0.017
0.590
<0.001
0.153
0.728

P value is significant. Pearson chi-square test was used for all categorical comparisons and the
independent t-test for continuous variables with equal variance
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Table 2. Descriptive statistics. Adherence results for HEDIS and PDC methodologies
Characteristics

1

Overall
adherence
Adherent

HEDIS1
N = 626
% (n)

PDC2
N =22.351
% (n)

37.38% (234)

50.37 % (11,259)

Non-adherent

Adherent

P Value

Non-adherent

Age, years
Age < 35
35 < Age <49
50 ≤ Age

% (n)
28.67 (80)
71.33 (199)
38.91 (86)
38. 91 (135)
53. 60 (67)
46. 40 (58)

P Value
<0.001*

% (n)
37. 12 (2442) 62.88 (4137)
50.53 (4186) 49. 47 (4098)
61. 85 (4631) 38. 15 (2857)

P Value
<0.001*

%(n)
64. 84 (83)

P Value
0.6091

% (n)
51.33 (3197)
48.67 (3031)

P Value
0.0758

Gender
Male

35. 16 (45)

Female

37.95 (189)

62.05 (309)

45.65 (21)

54.35 (25)

0.2678

61.35 (1603)

38.65 (1010)

<0.001*

Cardiovascular
Respiratory
Mental Health

44.05 (37)
56.10 (23)
42.03 (87)

55.95 (47)
43.90 (18)
57.97 (120)

0.1838
0.0123
0.0958

58.85 (1901)
62.19 (857)
54.38 (2587)

41.15 (1329)
37.81 (521)
45.62 (2170)

<0.001*
<0.001*
<0.001*

% (n)
39.40 (184)
37.79 (65)

60.60 (283)
62.21 (107)

% (n)

P Value

50.00 (8061)

Comorbid
Disease
Diabetes

Health Care
Utilization
Psychiatric visits
Hospitalization

% (n)

50.00 (8062)

P Value
0.0874
0.9264
P Value

% (n)

% (n)
56.00 (4574)
8.65 (1933)

44.00 (3594)
8.06 (1802)

P Value

P Value
<0.001*
0.0645

Therapy
Regimen
Polytherapy
SSRI3
SNRI4
Trazodone
TCA5
Bupropion

49.43 (130)
34.47 (142)
58.06 (18)
36.71 (29)
44.83 (13)
44.23 (23)

50.57 (133)
65.53 (270)
41.94 (13)
63.29 (50)
55.17 (16)
55.77 (29)

<0.001*
0.0450*
0.210
1.000
0.4342
0.2975

75.66 (5158)
48.41 (6121)
62.93 (1049)
56.21 (1490)
42.73 (949)
51.01 (1140)

24.34 (1659)
51.59 (6522)
37.07 (618)
43.79 (1161)
57.27 (1272)
48.99 (1095)

<0.001*
<0.001*
<0.001*
<0.001*
<0.001*
0.5471

Mirtazapine

38.10 (8)

61.90 (13)

1.000

44.10 (355)

63.90 (450)

0.0016

1

% (n)

P Value

HEDIS - patients have a diagnosis of depression
PDC- includes all users of antidepressants irrespective of diagnosis
3
SSRI-Selective Serotonin Reuptake Inhibitors Antidepressants,
4
SNRI-Selective Serotonin-Norepinephrine Reuptake Inhibitors Antidepressants,
5
TCA-Tricyclic antidepressants
Patients will be considered adherent to their medication if PDC >80% and non-adherent if PDC <80%.
*
P value is significant.
2
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Table 3. Likelihood of adherence associated with antidepressant use for HEDIS1 methodology.
Univariate Logistic Regression Analyses
Characteristic

Beta
Coefficient

Odds Ratio

95%
Confidence Interval

Age < 35
35 < Age <49
50 ≤ Age

0.4478*
1.0430*

1.565*
2.838*

Reference
1.077 - 2.275
1.834 - 4.389

Gender
Female
Male

-0.1206

0.886

Reference
0.591 - 1.330

Comorbid Disease
Diabetes
Cardiovascular
Respiratory
Mental Health

0.3697
0.3211
0.8174*
0.2938

1.447
1.379
2.265*
1.341

0.971 - 2.648
0.866 - 2.195
1.159 - 4.293
0.954 - 1.887

Health Care Utilization
Psychiatric visits
Hospitalization

0.3488
0.0242

Age, years

1.417
1.024

0.967 - 2.078
0.713 - 1.472

Therapy Regimen
Polytherapy
08895*
2.434*
1.746 - 3.392
SSRI2
-0.3604
0.697*
0.497 - 0.978
SNRI3
0.8875
2.429*
1.167 - 5.054
Trazodone
0.0328
0.968
0.593 - 1.578
TCA4
0.3238
1.382
0.653 - 2.928
Bupropion
0.3107
1.364
0.769 - 1.300
Mirtazapine
0.0316
1.032
0.421 - 2.528
1
HEDIS - patients have a diagnosis of depression
2
SSRI-Selective Serotonin Reuptake Inhibitors Antidepressants,
3
SNRI-Selective Serotonin-Norepinephrine Reuptake Inhibitors Antidepressants,
4
TCA-Tricyclic antidepressants
*

P value<=0.2 is significant.
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Table 4. Likelihood of adherence associated with antidepressant medication use for PDC1
methodology. Univariate Logistic Regression Analyses
Characteristic

Beta
Coefficient

Odds Ratio

95%
Confidence Interval

Age < 35
35 < Age <49
50 ≤ Age

0.5484*
1.0101*

1.730*
2.746*

Reference
1.620 - 1.849
2.564 - 2.940

Gender
Female
Male

0.0532

1.055

Reference
0.995 - 1.118

Comorbid Disease
Diabetes
Cardiovascular
Respiratory
Mental Health

0.5051*
0.4003*
0.5138*
0.2042*

1.657*
1.492*
1.672
1.227*

1.524 - 1.802
1.384 - 1.609
1.494 - 1.870
1.150 - 1.308

Health Care Utilization
Psychiatric visits
Hospitalization

0.3559*
0.0663

1.427
1.069

1.351 - 1.508
0.996 - 1.146

Age, years

Therapy Regimen
Polytherapy
1.5701*
4.807*
4.509 - 5.125
SSRI2
-0.1835*
0.832*
0.789 - 0.878
SNRI3
0.5539*
1.740*
1.570 - 1.929
Trazodone
0.2651*
1.304*
1.201 - 1.415
TCA4
-0.3428*
0.710
0.650 - 0.776
Bupropion
0.0272
1.028
0.942 - 1.121
Mirtazapine
0.2296*
1.258
1.092 - 1.405
1
PDC- includes all users of antidepressants irrespective of diagnosis
2
SSRI-Selective Serotonin Reuptake Inhibitors Antidepressants,
3
SNRI-Selective Serotonin-Norepinephrine Reuptake Inhibitors Antidepressants,
4
TCA-Tricyclic antidepressants
*

P value<=0.2 is significant for model selection.
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Table 5. Fitted Reduced Model for HEDIS1 methodology. Likelihood of antidepressant medication
adherence according to selected characteristics
Characteristic

Beta
Coefficient

Odds Ratio

0.3190*
0.9463*

1.376
2.576

Reference
0.932 - 2.030
1.626 - 4.083

Gender
Female
Male

-0.3017

0.740

Reference
0.481 – 1.138

Comorbid Disease
Respiratory
Mental Health

0.5567*
0.3213

1.745
1.379

0.894 - 3.406
0.964 - 1.973

2.214

1.570 - 3.121

Age, years
Age < 35
35 < Age <49
50 ≤ Age

Therapy Regimen
Polytherapy
0.3213*
1
HEDIS - patients have a diagnosis of depression
*
P < 0.05
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95%
Confidence Interval

Table 6. Fitted Reduced Model for PDC1 methodology. Likelihood of antidepressant medication
adherence according to selected characteristics

Characteristic

Beta
Coefficient

Odds Ratio

0.5484*
1.0101*

1.730
2.746

Reference
1.620 - 1.849
2.564 - 2.940

Gender
Female
Male

0.0532

1.055

Reference
0.995 - 1.118

Comorbid Disease
Diabetes
Cardiovascular
Respiratory
Mental Health

0.5051*
0.4003*
0.5138*
0.2042*

1.657
1.492
1.672
1.227

1.524 -1.802
1.384 - 1.609
1.594 - 1.870
1.150 - 1.308

Age, years
Age < 35
35 < Age <49
50 ≤ Age

95%
Confidence Interval

Therapy Regimen
Polytherapy
1.5701*
4.807
4.509 - 5.125
SNRI2
0.5339*
1.740
1.570 - 1.929
SSRI3
-0.1835*
0.832
0.789 - 0.878
1
PDC- includes all users of antidepressants irrespective of diagnosis
2
SSRI-Selective Serotonin Reuptake Inhibitors Antidepressants,
3
SNRI-Selective Serotonin-Norepinephrine Reuptake Inhibitors Antidepressants,
*

P < 0.05
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Figure 3. Correlation between continuous adherence measures comparing HEDIS method and PDC
adherence calculation method applied to HEDIS cohort
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APPENDIX A
ICD-9 CODES TO IDENTIFY DIABETES

25000
25032
25070
36202

25001
25033
25071
36203

25002
25040
25072
36204

25003
25041
25073
36205

25010
25042
25080
36206

25011
25043
25081
36207

25012
25050
25082
36641

25013
25051
25083
64801

25020
25052
25090
64802

DRUG THERAPEUTIC CLASS TO IDENTIFY DIABETES
C4G C4F C4K C4L C4N C4R C4S C4T
-Diabetes mellitus type I
-Diabetes mellitus type II
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25021
25053
25091
64803

25022 25023 25030 25031
25060 25061 25062 25063
25092 25093 3572 36201
64804

APPENDIX B
ICD-9 CODES TO IDENTIFY CARDIOVASCULAR DISEASE

401 40100 4010 4011 4019 425 4250 4251 42511 42518 4352 4253 4254 4255 4257
4258 4259 428
4280
4281 4282 42820 42821 42822 42823 4283 42830 42831 42832
42833 4284 42840 42841 42842 42843 4289 413 4130 41300 41310 41390 41000 41001
41002 41010 41011 41012 41020 41021 41022 41030 41031 41032 41040 41041 41042
41050 41051 41052 41060 41061 41062 41070 41071 41080 41081 41082 41090 41091
41092 41100 41110 41181 41189 41200 41300 41310 41390 41401 41403 41404 41405
41406 41407 41410 41411 41412 41419 41480 41490 42800 42810 42820 42821 42822
42823 42830 42831 42832 42833 42840
42841 42842 42843 42890 40201 40211 40291
40401 40411 40491 40403 40413 40493 39891

-High blood pressure
-Hyperpiesia
-Hypertensive heart disease
-Malignant hypertensive heart disease
-Benign hypertensive heart disease
-Unspecified hypertensive heart disease
-Acute myocarditis
-Acute percarditis
-Heart failure
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APPENDIX C
ICD-9 CODES TO IDENTITY RESPIRATORY DISEASE

493 4930 29300 49301 49302 4931 49310 49311 49312 4938 49381 49382 4939
49390 49391 49392 4932 49320 49321 49322 496 4960 49600 49100 466 491 4910 49100
4911 4912 49120 49121 49122 4918 4919 4912 49120 49121 49122

-Bronchitis
-Emphysema
-Asthma
-Bronchiectasis
-Extrinsic allergic alveolitis
-Chronic airway obstruction
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APPENDIX D
ICD-9 CODES TO IDENTIFY MENTAL HEALTH DISEASE

296 2960 29600 29601 29602 29603 29604 29605 29606 2961 29611 29612 29613 29614
29615 29616 2964 29640 29616 2964 29640 29641 29642 29643 29644 29645 29646 2965
29650 29651 29652 29653 29654 29656 2966 29660 29662 29663 29664 29665 2967 300 3000
30000 30001 30002 30009 30021 3003 3009 295 29500 30001 30002 30009 30021 3003 3009 295
2950 29500 29501 29502 29503 29504 29505 2951 29510 29511 29512 29513 29515 2952 29520
29521 29522 29523 29524 29525 2953 29530 29531 25932 29533 29534 29535 2954 29540
29541 29542 29543 29544 29545 2955 29550 29551 29552 29553 29554 29555 2956 29561 29562
29563 29564 29565 2957 29570 29571 29572 29573 29574 29575 2958 29580 29581 29582
29583 29584 29585 2959 29591 29592 29593 29594 29595

-Episodic mood disorders
-Bipolar disorder
-Manic disorder
-Major depressive disorder
-Schizophrenia
-Anxiety
-Phobic disorders
-Somatoform disorders

39

APPENDIX E
ANTIDEPRESSANT MEDICATIONS LIST



Selective Serotonin Reuptake Inhibitors Antidepressants (SSRIs)
Citalopram; Escitalopram; Fluoxetine; Fluvoxamine; Paroxetine; Sertraline



Selective Serotonin-Norepinephrine Reuptake Inhibitors Antidepressants (SSNRIs)
Desvenlafaxine; Duloxetine; Venlafaxine;



Tetracyclic Antidepressants (TeCAs)
Maprotiline; Mirtazapine;



Monoamine Oxidase Inhibitors (MAOIs)
Isocarboxazid; Selegiline; Phenelzine; Tranylcypromine



Phenylpiperazine Antidepressants
Nefazodone; Trazodone



Psychotherapeutic combinations
Amitriptyline-clordiazepoxide; Amitriptyline-perphenazine ; Fluoxetine-olanzapine;



Tricyclic antidepressants (TCAs)
Amitriptyline; Amoxapine; Clomipramine; Desipramine; Doxepin; Imipramine;
Nortryptiline; Protryptyline; Trimipramine



Miscellaneous Antidepressants
Bupropion; Vilazodone
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